First and second generation recombinant factor VIII concentrates in previously untreated patients: Recovery, safety, efficacy, and inhibitor development

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 3, 2002, Pages 273-276

  Lusher, Jeanne M ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Inhibitor antibodies to FVIII; Previously untreated patient; rFVIII; Safety trials; Second generation rFVIII preparations

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; F8 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ANTIBODY TITER; BLOOD CLOTTING; CHILD; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HAMSTER; HEMOPHILIA A; HUMAN; INCIDENCE; INHIBITION KINETICS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; ANTIBODY PRODUCTION; DRUG SCREENING; IMMUNOLOGY; SAFETY;

ANTIBODY FORMATION; AUTOANTIBODIES; CLINICAL TRIALS; CONSUMER PRODUCT SAFETY; DRUG EVALUATION; FACTOR VIII; HEMOPHILIA A; HUMAN; RECOMBINANT PROTEINS; HUMANS;

EID: 0036017374     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-32662     Document Type: Review

References (20)

1. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A
2. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A
3. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy and inhibitor development after seven study years
4. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: Incidence of inhibitor and evaluation of immune tolerance
5. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A
6. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs): A 6.5 year update
7. Transient inhibitors in patients with hemophilia A
8. Manufacturing and characterization of a new B-domain deleted recombinant factor VIII, r-VIII SQ
9. Recombinant clotting factor concentrates
10. Influences of phospholipid on the assessment of factor VIII activity
11. Recombinant B-domain deleted FVIII (rVIII SQ): Pharmacokinetics and initial safety aspects in hemophilia A patients
12. Discrepancies in potency assessment of recombinant FVIII concentrates
13. Second generation, B-domain deleted recombinant factor VIII
14. Safety, efficacy and inhibitor development in previously untreated patients (PUPs) treated exclusively with B-domain deleted recombinant FVIII (BDD rFVIII)
15. Inhibitor formation monitoring in pediatric patients with severe hemophilia A receiving a second-generation rFVIII concentrate formulated with sucrose
16. The Nijmegen modification of the Bethesda assay for factor VIII inhibitors: Improved specificity and reliability
17. Incidence of development of factor VIII and factor IX inhibitors in haemophilias
18. Incidence of inhibitors in haemophilia A patients - A review of recent studies of recombinant and plasma-derived factor VIII concentrates
19. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands
20. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate